Welcome to our dedicated page for Gyre Therapeutics SEC filings (Ticker: GYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gyre Therapeutics, Inc. filings document a commercial-stage biopharmaceutical issuer with U.S. and China operations, revenue from Gyre Pharmaceuticals, and a pipeline centered on anti-fibrotic therapies and targeted protein degradation assets. Form 8-K reports cover operating results, business updates, CDE/NMPA regulatory disclosures for F351, and clinical-program updates for Hydronidone and pirfenidone.
Proxy and material-event filings describe governance matters, shareholder voting items, material agreements, capital-structure disclosures and the completed Cullgen acquisition, including preferred-stock and common-stock conversion mechanics. The record also includes Regulation FD disclosures addressing commercial products, research spending and pipeline development.
Gyre Therapeutics director Carmichael Gordon received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share, expire on June 10, 2036, and will vest in 12 equal monthly installments through June 10, 2027, contingent on continued service.
GYRE THERAPEUTICS, INC. director David M. Epstein received a grant of stock options to acquire 40,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on June 10, 2036.
The award was made as a compensation-related grant, with no cash purchase by the insider at grant. According to the terms, the options will vest in 12 equal monthly installments through June 10, 2027, so long as Epstein continues to provide service to the company through each vesting date.
GYRE THERAPEUTICS, INC. director Dan Weng received a stock option grant covering 40,000 shares of common stock. The option has an exercise price of $5.95 per share and expires on June 10, 2036.
The award vests in 12 equal monthly installments through June 10, 2027, conditioned on continued service. After this grant, Weng holds stock options for 40,000 underlying shares directly, reflecting routine equity-based compensation rather than an open-market transaction.
GYRE THERAPEUTICS, INC. director Renate Parry received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on June 10, 2036. According to the disclosure, the award vests in 12 equal monthly installments through June 10, 2027, contingent on Parry’s continued service to the company. This is a compensation-related acquisition, with no open‑market buying or selling reported in this filing.
GYRE THERAPEUTICS, INC. director Zhang Ping received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share, expire on June 10, 2036, and vest in 12 equal monthly installments through June 10, 2027 as long as service continues.
Gyre Therapeutics director Rodney L. Nussbaum received a new stock option grant for 40,000 shares of common stock. The option, with an exercise price of $5.95 per share, gives him the right to buy Gyre Therapeutics stock at that price until June 10, 2036.
The award was reported as a compensation-related grant, not an open-market purchase or sale. The option will vest in 12 equal monthly installments through June 10, 2027, subject to his continued service with the company. After this grant, he holds options for 40,000 underlying shares directly.
Gyre Therapeutics, Inc. is registering 30,221,531 shares of Common Stock for resale by selling stockholders. The registration covers up to 11,735,356 Common Shares and 18,486,175 Conversion Series B Shares issuable upon conversion of 3,697,235 Series B Preferred Shares, with conversion subject to stockholder approval required by Nasdaq (the "Conversion Approval").
The company states it will receive no proceeds from sales of the Resale Shares; net proceeds will be received by the selling stockholders. The filing arises from the May 4, 2026 merger with Cullgen and implements registration rights under a Registration Rights Agreement. Shares outstanding were 111,488,849 as of May 31, 2026.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported a series of option exercises paired with open-market sales of common stock. On June 9, 10, and 18, he exercised stock options at $0.75 per share to acquire a total of 11,000 shares of common stock, then sold 11,000 shares in open-market transactions at prices reported around $6.15–$6.35 per share. A footnote states some sales were reported as a weighted average with individual trades between $6.20 and $6.30 per share. After these transactions, Ye directly holds 700,000 shares of Gyre Therapeutics common stock.
Gyre Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders. There were 96,994,001 shares of common stock entitled to vote as of the April 16, 2026 record date.
Stockholders elected Class II directors David M. Epstein, Ph.D. and Dan Weng, M.D. to serve until the 2029 annual meeting. A non-binding advisory vote approved executive compensation. Stockholders also ratified Grant Thornton Zhitong Certified Public Accountants LLP as independent auditor for 2026 and approved issuing common stock upon conversion of Series B Convertible Preferred Stock in accordance with Nasdaq Listing Rule 5635(a).
GYRE THERAPEUTICS, INC. Chief Operating Officer Ye Weiguo reported a same‑day option exercise and share sale. He exercised options to acquire 2,800 shares of common stock at an exercise price of $0.75 per share, then sold 2,800 shares in an open‑market transaction at a weighted average price of $6.17 per share.
After these transactions, Ye directly holds 700,000 shares of common stock. The exercised options covered 2,800 shares of common stock originally granted as a stock option (right to buy) that was fully vested.